Dexcom
DEXCOM, INC.
Key figures
Period Jan 2025 to Dec 2025ConsolidatedU.S. GAAP
RevenueDisclosed
US$4.7B
Operating marginCalculated
19.6%
Net assets to total assetsCalculated
43.3%
Company profile
Tables scroll sideways
Disclosed data
Profitability
★★★★☆position among all companies
19.6%
Growth (revenue, 4-year average)
★★★★★position among all companies
17.5%
Capital efficiency
★★★★★position among all companies
30.5%
Revenue and profit
Performance, financial position and capital allocation
Dexcom
Recent performance trends
Dexcom
Cash flow trends
Consolidated indicators (9 items)
| Item | 4 years ago | 3 years ago | 2 years ago | Last year | This year |
|---|---|---|---|---|---|
| Net sales | US$2.4 billion | US$2.9 billion | US$3.6 billion | US$4.0 billion | US$4.7 billion |
| Operating income | US$0.3 billion | US$0.4 billion | US$0.6 billion | US$0.6 billion | US$0.9 billion |
| Net income | US$0.2 billion | US$0.3 billion | US$0.5 billion | US$0.6 billion | US$0.8 billion |
| Total assets | US$4.9 billion | US$5.4 billion | US$6.3 billion | US$6.5 billion | US$6.3 billion |
| Shareholders' equity | US$2.0 billion | US$2.1 billion | US$2.1 billion | US$2.1 billion | US$2.7 billion |
| Net cash provided by (used in) operating activities | US$0.4 billion | US$0.7 billion | US$0.7 billion | US$1.0 billion | US$1.4 billion |
| Net cash provided by (used in) investing activities | US$-0.2 billion | US$-0.5 billion | US$-0.5 billion | US$-0.2 billion | US$0.5 billion |
| Net cash provided by (used in) financing activities | US$10.40 million | US$-0.6 billion | US$-0.3 billion | US$-0.7 billion | US$-1.7 billion |
| Cash and cash equivalents | US$1.1 billion | US$0.6 billion | US$0.6 billion | US$0.6 billion | US$0.9 billion |
Revenue scale in the same industry
Dexcom
Instruments and medical devices: 43 companies · revenue · largest first・each company’s latest fiscal year・Consolidated・Disclosed
- 1 Thermo Fisher ScientificFY Dec 2025 US$44.6B
- 2 Northrop Grumman Corp /DE/FY Dec 2025 US$42.0B
- 3 MedtronicFY Apr 2026 US$36.4B
- … 23 companies
- 27 VeraltoFY Dec 2025 US$5.5B
- 28 Keysight TechnologiesFY Oct 2025 US$5.4B
- 29 DexcomThis companyFY Dec 2025 US$4.7B
- 30 IlluminaFY Dec 2025 US$4.3B
- 31 FortiveFY Dec 2025 US$4.2B
- … 12 companies
Sources and methodology
Basic indicators
| Item | Value | Consolidated / Non-consolidated | Source |
|---|---|---|---|
| Purchase of property, plant and equipment | US$0.4 billion | Consolidated | Disclosed |
| Cash and cash equivalents | US$0.9 billion | Consolidated | Disclosed |
| Net cash provided by (used in) financing activities | US$-1.7 billion | Consolidated | Disclosed |
| Net cash provided by (used in) investing activities | US$0.5 billion | Consolidated | Disclosed |
| Net cash provided by (used in) operating activities | US$1.4 billion | Consolidated | Disclosed |
| Depreciation and amortization | US$0.3 billion | Consolidated | Disclosed |
| Net assets | US$2.7 billion | Consolidated | Disclosed |
| Net sales | US$4.7 billion | Consolidated | Disclosed |
| Operating income | US$0.9 billion | Consolidated | Disclosed |
| Net income | US$0.8 billion | Consolidated | Disclosed |
| Total assets | US$6.3 billion | Consolidated | Disclosed |
| Purchase of treasury stock | US$0.5 billion | Consolidated | Disclosed |
| Operating margin | 19.6% | Consolidated | Calculated |
| Net assets to total assets | 43.3% | Consolidated | Calculated |
| Net margin | 17.9% | Consolidated | Calculated |
| Return on equity | 30.5% | Consolidated | Calculated |